JOURNAL ONKOLOGIE – STUDIE
EPIK-B3 Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation
Rekrutierend
NCT-Nummer:
NCT04251533
Studienbeginn:
Juni 2020
Letztes Update:
19.10.2020
Wirkstoff:
Alpelisib, Placebo, Nab-Paclitaxel
Indikation (Clinical Trials):
Triple Negative Breast Neoplasms, Breast Neoplasms
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 3
Sponsor:
Novartis Pharmaceuticals
Collaborator:
-
Studienleiter
Study Director
Novartis Pharmaceuticals
Kontakt
Kontakt:
Phone: 1-888-669-6682
E-Mail: novartis.email@novartis.com» Kontaktdaten anzeigen
Kontakt:
Phone: +41613241111
» Kontaktdaten anzeigen
Studienlocations (3 von 50)
Novartis Investigative Site
88212 Ravensburg
(Baden-Württemberg)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
80637 Muenchen
(Bayern)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
42551 Velbert
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
88212 Ravensburg
(Baden-Württemberg)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
80637 Muenchen
(Bayern)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
42551 Velbert
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Novartis Investigative Site
91054 Erlangen
(Bayern)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
04103 Leipzig
(Sachsen)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-MapsComprehensive Cancer Centers of Nevada CCC of Nevada (1)
89109 Las Vegas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Krissy Gunn
Phone: 702-952-3426
E-Mail: krossy.gunn@usoncology.com» Ansprechpartner anzeigenCleveland Clinic Foundation Taussig Cancer Center
44195 Cleveland
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Holly Sasak
Phone: 216-444-6833
E-Mail: SASAKH@ccf.org» Ansprechpartner anzeigenTexas Oncology, P.A. Austin
76022 Bedford
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Patricia Janeczko
Phone: 512-421-4163
E-Mail: patricia.janeczko@usoncology.com» Ansprechpartner anzeigenTexas Oncology PA Dallas Presbyterian Hospital SC
75231 Dallas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Carly Trainor
Phone: 214-265-2080
E-Mail: carly.trainor@usoncology.com» Ansprechpartner anzeigenTexas Oncology Texas Oncology - Denton
75246 Dallas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Phone: 940-382-1022» Ansprechpartner anzeigenEl Paso, Texas Oncology
79902 El Paso
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Ana McBirnie
E-Mail: ana.mcbirnie@usoncology.com» Ansprechpartner anzeigenNovartis Investigative Site
6150 Murdoch
AustraliaRekrutierend» Google-MapsNovartis Investigative Site
6009 Nedlands
AustraliaRekrutierend» Google-MapsNovartis Investigative Site
03102-002 Sao Paulo
BrazilRekrutierend» Google-MapsNovartis Investigative Site
49055 Angers Cedex 02
FranceRekrutierend» Google-MapsNovartis Investigative Site
25030 Besancon Cedex
FranceRekrutierend» Google-MapsNovartis Investigative Site
63011 Clermont-Ferrand
FranceRekrutierend» Google-MapsNovartis Investigative Site
94010 Creteil
FranceRekrutierend» Google-MapsNovartis Investigative Site
57085 Metz
FranceRekrutierend» Google-MapsNovartis Investigative Site
75475 Paris Cedex 10
FranceRekrutierend» Google-MapsNovartis Investigative Site
86000 Poitiers
FranceRekrutierend» Google-MapsNovartis Investigative Site
51100 Reims
FranceRekrutierend» Google-MapsNovartis Investigative Site
44805 Saint-Herblain Cédex
FranceRekrutierend» Google-MapsNovartis Investigative Site
4032 Debrecen
HungaryRekrutierend» Google-MapsNovartis Investigative Site
6000 Kecskemet
HungaryRekrutierend» Google-MapsNovartis Investigative Site
H 2800 Tatabanya
HungaryRekrutierend» Google-MapsNovartis Investigative Site
84101 Be'er Sheva
IsraelRekrutierend» Google-MapsNovartis Investigative Site
6423906 Tel Aviv
IsraelRekrutierend» Google-MapsNovartis Investigative Site
98158 Messina
ItalyRekrutierend» Google-MapsNovartis Investigative Site
00128 Roma
ItalyRekrutierend» Google-MapsNovartis Investigative Site
46050 Petaling Jaya
MalaysiaRekrutierend» Google-MapsNovartis Investigative Site
59100 Kuala Lumpur
MalaysiaRekrutierend» Google-MapsNovartis Investigative Site
NO 0450 Oslo
NorwayRekrutierend» Google-MapsNovartis Investigative Site
4019 Stavanger
NorwayRekrutierend» Google-MapsNovartis Investigative Site
163045 Arkhangelsk
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
454048 Chelyabinsk
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
117997 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
123056 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
143423 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
196603 Pushkin Saint Petersburg
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
812 50 Bratislava
SlovakiaRekrutierend» Google-MapsNovartis Investigative Site
041 91 Kosice
SlovakiaRekrutierend» Google-MapsNovartis Investigative Site
28041 Madrid
SpainRekrutierend» Google-MapsNovartis Investigative Site
5000 Aarau
SwitzerlandRekrutierend» Google-MapsNovartis Investigative Site
8008 Zurich
SwitzerlandRekrutierend» Google-MapsNovartis Investigative Site
40447 Taichung
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
10002 Taipei
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
10449 Taipei
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
NG5 1PB Nottingham
United KingdomRekrutierend» Google-Maps
Alle anzeigen 91054 Erlangen
(Bayern)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
04103 Leipzig
(Sachsen)
GermanyRekrutierend» Google-MapsNovartis Investigative Site
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-MapsComprehensive Cancer Centers of Nevada CCC of Nevada (1)
89109 Las Vegas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Krissy Gunn
Phone: 702-952-3426
E-Mail: krossy.gunn@usoncology.com» Ansprechpartner anzeigenCleveland Clinic Foundation Taussig Cancer Center
44195 Cleveland
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Holly Sasak
Phone: 216-444-6833
E-Mail: SASAKH@ccf.org» Ansprechpartner anzeigenTexas Oncology, P.A. Austin
76022 Bedford
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Patricia Janeczko
Phone: 512-421-4163
E-Mail: patricia.janeczko@usoncology.com» Ansprechpartner anzeigenTexas Oncology PA Dallas Presbyterian Hospital SC
75231 Dallas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Carly Trainor
Phone: 214-265-2080
E-Mail: carly.trainor@usoncology.com» Ansprechpartner anzeigenTexas Oncology Texas Oncology - Denton
75246 Dallas
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Phone: 940-382-1022» Ansprechpartner anzeigenEl Paso, Texas Oncology
79902 El Paso
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Ana McBirnie
E-Mail: ana.mcbirnie@usoncology.com» Ansprechpartner anzeigenNovartis Investigative Site
6150 Murdoch
AustraliaRekrutierend» Google-MapsNovartis Investigative Site
6009 Nedlands
AustraliaRekrutierend» Google-MapsNovartis Investigative Site
03102-002 Sao Paulo
BrazilRekrutierend» Google-MapsNovartis Investigative Site
49055 Angers Cedex 02
FranceRekrutierend» Google-MapsNovartis Investigative Site
25030 Besancon Cedex
FranceRekrutierend» Google-MapsNovartis Investigative Site
63011 Clermont-Ferrand
FranceRekrutierend» Google-MapsNovartis Investigative Site
94010 Creteil
FranceRekrutierend» Google-MapsNovartis Investigative Site
57085 Metz
FranceRekrutierend» Google-MapsNovartis Investigative Site
75475 Paris Cedex 10
FranceRekrutierend» Google-MapsNovartis Investigative Site
86000 Poitiers
FranceRekrutierend» Google-MapsNovartis Investigative Site
51100 Reims
FranceRekrutierend» Google-MapsNovartis Investigative Site
44805 Saint-Herblain Cédex
FranceRekrutierend» Google-MapsNovartis Investigative Site
4032 Debrecen
HungaryRekrutierend» Google-MapsNovartis Investigative Site
6000 Kecskemet
HungaryRekrutierend» Google-MapsNovartis Investigative Site
H 2800 Tatabanya
HungaryRekrutierend» Google-MapsNovartis Investigative Site
84101 Be'er Sheva
IsraelRekrutierend» Google-MapsNovartis Investigative Site
6423906 Tel Aviv
IsraelRekrutierend» Google-MapsNovartis Investigative Site
98158 Messina
ItalyRekrutierend» Google-MapsNovartis Investigative Site
00128 Roma
ItalyRekrutierend» Google-MapsNovartis Investigative Site
46050 Petaling Jaya
MalaysiaRekrutierend» Google-MapsNovartis Investigative Site
59100 Kuala Lumpur
MalaysiaRekrutierend» Google-MapsNovartis Investigative Site
NO 0450 Oslo
NorwayRekrutierend» Google-MapsNovartis Investigative Site
4019 Stavanger
NorwayRekrutierend» Google-MapsNovartis Investigative Site
163045 Arkhangelsk
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
454048 Chelyabinsk
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
117997 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
123056 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
143423 Moscow
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
196603 Pushkin Saint Petersburg
Russian FederationRekrutierend» Google-MapsNovartis Investigative Site
812 50 Bratislava
SlovakiaRekrutierend» Google-MapsNovartis Investigative Site
041 91 Kosice
SlovakiaRekrutierend» Google-MapsNovartis Investigative Site
28041 Madrid
SpainRekrutierend» Google-MapsNovartis Investigative Site
5000 Aarau
SwitzerlandRekrutierend» Google-MapsNovartis Investigative Site
8008 Zurich
SwitzerlandRekrutierend» Google-MapsNovartis Investigative Site
40447 Taichung
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
10002 Taipei
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
10449 Taipei
TaiwanRekrutierend» Google-MapsNovartis Investigative Site
NG5 1PB Nottingham
United KingdomRekrutierend» Google-Maps
Studien-Informationen
Brief Summary:The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss without PIK3CA mutation (Study Parts B1 and B2)
Ein-/Ausschlusskriterien
Inclusion Criteria:- Subject has histologically confirmed diagnosis of advanced (loco-regionally recurrent and not amenable to curative therapy, or metastatic (stage IV)) TNBC
- Subject has either a measurable disease per RECIST 1.1 criteria or, if no measurable disease is present, then at least one predominantly lytic bone lesion or mixed lytic-blastic bone lesion with identifiable soft tissue component (that can be evaluated by CT/MRI) must be present Part B1: patients must have measurable disease
- Subject has adequate tumor tissue to identify the PIK3CA mutation status (either carrying a mutation or without a mutation) and the PTEN loss status; both of which will determine whether the subject can be allocated to Part A - PIK3CA mutation regardless of PTEN status; or to Part B - PTEN loss without a PIK3CA mutation
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Subject has received no more than one line of therapy for metastatic disease.
- Subject has adequate bone marrow and organ function
Exclusion Criteria:
- Subject has received prior treatment with any PI3K, mTOR or AKT inhibitor
- Subject has a known hypersensitivity to alpelisib, nab-paclitaxel or to any of their excipients
- Subject has not recovered from all toxicities related to prior anticancer therapies to NCI CTCAE version 4.03 Grade ≤1; with the exception of alopecia
- Subject has central nervous system (CNS) involvement
- Subject with an established diagnosis of diabetes mellitus type I or uncontrolled type II based on Fasting Plasma Glucose and HbA1c
- Subject has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) based on investigator discretion
- Subject has a history of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis
- Subject has currently documented pneumonitis/interstitial lung disease
- Subject has a history of severe cutaneous reactions, such as Steven-Johnson Syndrome (SJS), erythema multiforme (EM),Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Syndrome (DRESS)
- Subject with unresolved osteonecrosis of the jaw
Other protocol-defined inclusion/exclusion criteria apply.
Studien-Rationale
Primary outcome:1. Progression-free Survival (PFS) Per Investigator Assessment in Study part A (Time Frame - Once approximately 192 PFS events in Study Part A had been observed, up to 35 months):
PFS, defined as time from the date of randomization to the date of the first documented progression or death due to any cause. PFS will be assessed via a local radiology assessment according to RECIST 1.1
2. Progression-free Survival (PFS) Per Investigator Assessment in Study part B2 (Time Frame - Once approximately 192 PFS events in Study Part B2 had been observed, up to 22 months):
PFS, defined as time from the date of randomization to the date of the first documented progression or death due to any cause. PFS will be assessed via a local radiology assessment according to RECIST 1.1
3. Overall Response Rate (ORR) based on local radiology assessments in subjects with measurable disease at baseline in study Part B1 (Time Frame - Up to 6 months):
ORR is defined as the proportion of subjects with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1
Secondary outcome:
1. Overall Survival (OS) in Study Part A (Time Frame - Up to 66 months):
OS is defined as the time from date of randomization to date of death due to any cause
2. Overall Survival (OS) in Study Part B2 (Time Frame - Up to 41 months):
OS is defined as the time from date of randomization to date of death due to any cause
3. Overall response rate (ORR) with confirmed response in Study Part A (Time Frame - Up to 35 months):
ORR with confirmed response is the proportion of subjects with BOR of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1
4. Overall response rate (ORR) with confirmed response in Study Part B2 (Time Frame - Up to 22 months):
ORR with confirmed response is the proportion of subjects with BOR of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1
5. Clinical benefit rate (CBR) with confirmed response in Study Part A (Time Frame - Up to 35 months):
Clinical benefit rate (CBR) with confirmed response is defined as the proportion of subjects with a best overall response of confirmed complete response (CR), or confirmed partial response (PR), or an overall response of stable disease (SD) lasting for a duration of at least 24 weeks. CR, PR, and SD are defined as per local review according to RECIST 1.1
6. Clinical benefit rate (CBR) with confirmed response in Study Part B1 (Time Frame - Up to 6 months):
Clinical benefit rate (CBR) with confirmed response is defined as the proportion of subjects with a best overall response of confirmed complete response (CR), or confirmed partial response (PR), or an overall response of stable disease (SD) lasting for a duration of at least 24 weeks. CR, PR, and SD are defined as per local review according to RECIST 1.1
7. Clinical benefit rate (CBR) with confirmed response in Study Part B2 (Time Frame - Up to 22 months):
Clinical benefit rate (CBR) with confirmed response is defined as the proportion of subjects with a best overall response of confirmed complete response (CR), or confirmed partial response (PR), or an overall response of stable disease (SD) lasting for a duration of at least 24 weeks. CR, PR, and SD are defined as per local review according to RECIST 1.1
8. Time to response (TTR) in Study Part A (Time Frame - Up to 35 months):
Time to response (TTR) is defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR are based on tumor response data as per local review and according to RECIST 1.1
9. Time to response (TTR) in Study Part B1 (Time Frame - Up to 6 months):
Time to response (TTR) is defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR are based on tumor response data as per local review and according to RECIST 1.1
10. Time to response (TTR) in Study Part B2 (Time Frame - Up to 22 months):
Time to response (TTR) is defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR are based on tumor response data as per local review and according to RECIST 1.1
11. Duration of Response (DOR) with confirmed response in Study Part A (Time Frame - Up to 35 months):
Duration of response (DOR) with confirmed response only applies to subjects whose best overall response is confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer
12. Duration of Response (DOR) with confirmed response in Study Part B1 (Time Frame - Up to 6 months):
Duration of response (DOR) with confirmed response only applies to subjects whose best overall response is confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer
13. Duration of Response (DOR) with confirmed response in Study Part B2 (Time Frame - Up to 22 months):
Duration of response (DOR) with confirmed response only applies to subjects whose best overall response is confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying cancer
14. Overall Survival (OS) in Study Part B1 (Time Frame - Up to 6 months):
OS is defined as the time from date of enrolment to date of death due to any cause
15. Progression-free Survival (PFS) Per Investigator Assessment in Study part B1 (Time Frame - Up to 6 months):
PFS, defined as time from the date of enrolment to the date of the first documented progression or death due to any cause. PFS will be assessed via a local radiology assessment according to RECIST 1.1
16. Plasma concentrations of alpelisib - Part A (Time Frame - Up to 35 months):
Summary statistics of plasma alpelisib concentrations by time point in study Part A
17. Plasma concentrations of alpelisib - Part B1 (Time Frame - Up to 6 months):
Summary statistics of plasma alpelisib concentrations by time point in study Part B1
18. Plasma concentrations of alpelisib -Part B2 (Time Frame - up to 22 months):
Summary statistics of plasma alpelisib concentrations by time point in study Part B2
19. Plasma concentrations of paclitaxel - Part A (Time Frame - Up to 35 months):
Summary statistics of plasma paclitaxel concentrations by time point in study Part A
20. Plasma concentrations of paclitaxel - Part B1 (Time Frame - up to 6 months):
Summary statistics of plasma paclitaxel concentrations by time point in study Part B1
21. Change from baseline in the global health status/Quality of life (QoL) scale score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) in study Part A (Time Frame - Up to 35 months):
Summary of composite measure of change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment
22. Change from baseline in the global health status/QoL scale score of the EORTC QLQ-C30 in study Part B2 (Time Frame - Up to 22 months):
Summary of composite measure of change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment
23. Time to 10% definitive deterioration in the global health status/QOL scale score of the EORTC QLQ-C30 in study Part A (Time Frame - Up to 35 months):
Definitive deterioration: time from date of randomization to date of event, defined as at least a 10% worsening from baseline with no later improvement above this threshold observed during the course of the treatment or until death due to any cause, in the global health status/QOL scale score of EORTC QLQ-C30, a questionnaire to assess the quality of life of cancer patients. The questionnaire contains 30 items & is composed of both multi-item scales & single-item measures based on the patient's experience over the past week. This includes 5 functional scales, 3 symptom scales, 6 single items & a global health status/QoL scale. The scales & single-item measures range in score from 0 - 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems
24. Time to 10% definitive deterioration in the global health status/QOL scale score of the EORTC QLQ-C30 in study Part B2 (Time Frame - Up to 22 months):
Definitive deterioration: time from date of randomization to date of event, defined as at least a 10% worsening from baseline with no later improvement above this threshold observed during the course of the treatment or until death due to any cause, in the global health status/QOL scale score of EORTC QLQ-C30, a questionnaire to assess the quality of life of cancer patients. The questionnaire contains 30 items & is composed of both multi-item scales & single-item measures based on the patient's experience over the past week. This includes 5 functional scales, 3 symptom scales, 6 single items & a global health status/QoL scale. The scales & single-item measures range in score from 0 - 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems
25. PFS based on local radiology assessments using RECIST 1.1 criteria for subjects by PIK3CA mutation status measured in baseline ctDNA in study Part A (Time Frame - Up to 35 months):
PFS in patients with PIK3CA mutation as measured in ctDNA
26. PFS based on local radiology assessments using RECIST 1.1 criteria for subjects by PIK3CA mutation status measured in baseline ctDNA in study Part B2 (Time Frame - Up to 22 months):
PFS in patients with PIK3CA mutation as measured in ctDNA
27. Time to definitive deterioration of the Eastern Cooperative Oncology Group (ECOG) performance status (PS) from baseline in Study Part A (Time Frame - Up to 35 months):
Definitive deterioration of ECOG PS is defined as the time from the date of randomization to the date of event defined as a worsening of at least once category from baseline in ECOG PS with no later improvement above this threshold observed during the course of the treatment or until death due to any cause
28. Time to definitive deterioration of the ECOG performance status from baseline in Study Part B2 (Time Frame - Up to 22 months):
Definitive deterioration of ECOG PS is defined as the time from the date of randomization to the date of event defined as a worsening of at least once category from baseline in ECOG PS with no later improvement above this threshold observed during the course of the treatment or until death due to any cause
Studien-Arme
- Experimental: alpelisib + nab-paclitaxel
Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Single arm Open label in Study Part B1 - Placebo Comparator: placebo + nab-paclitaxel
Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Not applicable in Study Part B1
Geprüfte Regime
- alpelisib (BYL719):
300 mg orally once per day (QD) - placebo (alpelisib matching placebo):
300 mg orally once per day (QD) - nab-paclitaxel (abraxane):
100 mg/m² as IV infusion on Days 1, 8 and 15 of a 28-day cycle
Quelle: ClinicalTrials.gov